Cymabay Therapeutics Inc (CBAY) Return on Assets ROA from the fourth quarter of 2023 to fourth quarter of 2022 and for the year 2023, Average High and Low, Fundamental Ratios from Dec 31 2023 to Dec 31 2022 - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Cymabay Therapeutics Inc   (NASDAQ: CBAY)


Cymabay Therapeutics Inc 's ROA from the fourth quarter of 2023 to the fourth quarter of 2022 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Cymabay Therapeutics Inc 's ROA in the fourth quarter of 2023?
Cymabay Therapeutics Inc recorded a cumulative net loss of $-105 million during 12 months ending in the fourth quarter of 2023, resulting in a negative return on assets (ROA) of -31.01%.

However, within the Healthcare sector 524 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the third quarter of 2023 from 4188 to 4615.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Dec 31 2023)
IV. Quarter		 (Sep 30 2023)
III. Quarter		 (Jun 30 2023)
II. Quarter		 (Mar 31 2023)
I. Quarter		 (Dec 31 2022)
IV. Quarter
Y / Y Total Assets Change 207.67 % 183.24 % 27.53 % 22.27 % -30.74 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million -105 -90 -81 -107 -106
Return On Assets (TTM) -31.01 % -33.85 % -41.77 % -59.12 % -62.41 %
CBAY's Total Ranking # 4615 # 4188 # 4439 # 4848 # 5641
Total Assets (TTM) in million 436 451 227 245 142
Seq. Total Assets Change -3.29 % 99.01 % -7.61 % 73.04 % -10.97 %
Seq. Net Income Change - - - - -

CBAY's 5 Years Annual ROA >> Back to CBAY Management Effectiveness >> Compare CBAY ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 208
Sector # 525
Overall # 4516

Return On Assets Statistics
High Average Low
37.87 %
-67.26 %
-209.89 %
(Sep 30 2014)   (Sep 30 2016)



  News about Cymabay Therapeutics Inc Return on Assets ROA

CymaBay Announces European Medicines Agency Accepts Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis


CymaBay Therapeutics Inc (Nasdaq: CBAY) has recently announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for Seladelpar, a potential treatment for Primary Biliary Cholangitis (PBC). This comes after the company submitted applications for Seladelpar to the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) and the United States Food and Drug Administration (FDA).
The acceptance of the MAA by the EMA is a significant milestone for CymaBay, as it signals the beginning of the regulatory review process in Europe. Primary Biliary Cholangitis is a chronic, autoimmune liver disease that affects the bile ducts, leading to inflammation and damage. There is currently an unmet medical need for effective treatments for this condition, and Seladelpar has shown promise in preclinical and clinical studies.



Financial Statements
Cymabay Therapeutics Inc 's Assets $ 436 million CBAY's Balance sheet
Cymabay Therapeutics Inc 's Income $ -42 million Quarterly CBAY's Income Statement
CBAY's Income by Division See CBAY's Income by Division



Annual Return On Assets (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021		 (Dec 31 2020)
FY 2020		 (Dec 31 2019)
FY 2019
Y / Y Total Assets Change 207.67 % -29.93 % 31.52 % -25.23 % 10.16 %
Total Assets in million 436 142 202 154 206
Y / Y Net Income Change - - - - -
Net Income in million -105 -106 -90 -51 -103
Annual Return On Assets -24.16 % -74.77 % -44.48 % -33.15 % -49.97 %

CBAY's 5 Years Annual ROA >> Back to CBAY Management Effectiveness >> Compare CBAY ROA to its Competitors



More Return On Assets Ratios
CBAY's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
CBAY's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for CBAY's Competitors
Subscribers only: Roa for Cymabay Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for CBAY's Customers

You may also want to know
CBAY's Roi CBAY's Inventory Turnover Ratio CBAY's Growth Rates CBAY's Dividend Comparisons
CBAY's Profitability Ratios CBAY's Asset Turnover Ratio CBAY's Dividend Growth
CBAY's Roe CBAY's Valuation Ratios CBAY's Financial Strength Ratios CBAY's Dividend Payout Ratio



Companies with similar Return On Assets at Dec 31 2023, within Healthcare Sector ROA

Date modified: 2026-09-18T13:11:05+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.